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Abstract
Objective: Epidemiological studies have shown that low folate levels are associated with a high body
mass index (BMI). These findings have potentially important health implications and warrant further
investigation to determine whether a causal relationship exists and the direction of this relationship.
The methylenetetrahydrofolate reductase (MTHFR) C677T TT genotype is associated with reduced
folate availability and may be a surrogate for measuring folate levels. We sought to determine whether
MTHFR C677T genotype was associated with obesity.
Design: We carried out our study on four populations from three longitudinal studies based in the UK
and Denmark in which DNA for genotyping was obtained along with measures of obesity.
Methods: Our subjects were taken from the British Women’s Heart and Health Study (BWHHS), the
Avon Longitudinal Study of Parents and Children (two populations: mothers and children) and the
Copenhagen City Heart Study. We performed analyses separately by population, and then carried out a
meta-analysis, combining similar populations.
Results: Initial findings in the BWHHS suggested that the TT genotype may be associated with an
increased risk of obesity BMIR30, however, no association was found with BMI or central adiposity in
this cohort. This genotype was not associated with obesity in our other cohorts.
Conclusions: Our results suggest that the initial positive finding with obesity in the BWHHS was a
chance finding. Our findings do not support a causal effect of low folate on obesity.
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Introduction
Recent findings that low folate levels are associated with a
high body mass index (BMI) (1–3) have potentially
important health implications. The apparent association
warrants further investigation to determine whether a
causal relationship exists as the current obesity epidemic
is a major public health issue, affecting the whole
population irrespective of age, gender and ethnic group.
Folate supplementation of commonly consumed foods
(e.g. flour), currently being considered in the UK
(Scientific Advisory Committee on Nutrition. Folate and
Disease Prevention, TSO, London, 2006), could be a
potential population level intervention to reverse the
obesity epidemic if low folate levels are indeed causally
related to obesity.
Lower serum folate levels have been found to be
strongly associated with increased BMI in women of
childbearing age in two waves of the National Health
and Nutrition Examination Survey, each 10 kg/m2
increase in BMI was associated with a 15.6% decrease
in serum folate (P!0.001), an association that
persisted even after controlling for age, ethnicity, folate
intake and red blood cell folate (1). A further large cross-
sectional study of women in prenatal care replicated the
finding of an association between low serum folate levels
and obesity (2). Also, a small case–control study found
much higher plasma homocysteine, a biomarker of low
folate levels, among obese children and adolescents
compared with non-obese controls (3). Further, indirect
evidence for an association between low folate and
obesity is that high pre-pregnancy BMI has been
consistently found to be associated with neural tube
defects (4, 5), which are caused by low perinatal folate
levels (6).
It is possible that lower levels of serum folate are
observed among heavier women, simply because their
requirements are greater (1). Another plausible expla-
nation for the association between low folate status and
obesity could be confounding by dietary habits, since it
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is likely that those individuals who have a high-energy
diet will eat less fruit, vegetables and cereals and
thus have a lower folate intake. However, we have
observed an association between the MTHFR C677T TT
genotype, which is associated with reduced folate
availability (7), and obesity in the British Women’s
Heart and Health Study (BWHHS) (8). Clearly, this
genotype could not have been altered by adult BMI,
and it is not subject to confounding by lifestyle factors
(9, 10). Thus, our MTHFR genotype–obesity findings
suggest that folate levels may be causally related to
greater BMI and obesity.
A potential mechanism by which folate could
influence body mass and obesity is via epigenetic
control of gene expression. Methylation of cytosines
in CpG dinucleotides is an important epigenetic modifi-
cation, which affects gene expression and thus cellular
function. To a certain extent, methylation patterns can
be controlled by environmental factors such as intake
of dietary folate, which is an important donor of
methyl groups required for methylation. Folate depletion
in humans has been observed to diminish genomic DNA
methylation (11, 12). The hypothesis that epigenetic
changes including methylation are linked to adult
obesity is supported by the observation that in humans
several genes have been shown to exhibit changes in
expression that correlated closely with BMI and/or
waist/hip ratio (13). Further, obesity is one of the
symptoms of Prader–Willi syndrome that is caused by
irregular DNA methylation patterns in a given region on
chromosome 15q (14).
Preliminary analysis has shown that the MTHFR
C677T TT genotype was associated with an w20%
increase in the prevalence of obesity in the BWHHS,
although only very small differences in BMI were
observed by genotype (8). Since initial positive geno-
type–phenotype associations frequently fail to replicate
(15), we sought to examine the association of MTHFR
C677T genotype with BMI and obesity in two further
population-based cohorts and to present a full analysis in
the BWHHS.
Methods
Study population
We examined the association between the MTHFR
genotype in four distinct populations within three
cohort studies, namely the BWHHS, the Avon Longi-
tudinal Study of Parents and Children (two populations:
mothers and children) and the Copenhagen City Heart
Study (CCHS).
The British Women’s Heart and Health Study
(BWHHS) Between 1999 and 2001 4286 women
aged 60–79 years, who were randomly selected from 23
British towns were interviewed, examined, completed
medical questionnaires and had detailed reviews of their
medical records. Of 4286 women who participated in
the BWHHS, 3938 (92%) had complete data on all
anthropometric measurements and of these 3438
(87%) provided consent for genetic testing and had
adequate MTHFR genotype assays. Twenty women
were excluded because they had non-white ethnicity,
leaving a final sample of 3416.
The Avon Longitudinal Study of Parents and
Children (ALSPAC) A population-based prospective
study investigating factors that affect the health and
development of children and their parents. Pregnant
women living in Bristol, England, who had an expected
date of delivery between April 1991 and December
1992, were eligible. A total of 14 541 women enrolled
in the study. Extensive data have been collected on the
children and their mothers from pregnancy onwards by
questionnaire, abstraction from medical notes, record
linkage and by attendance at research clinics. Of 8128
women with genotype data, information on pre-
pregnancy BMI was available for 6952 (86%), 461
(7%) women were excluded due to non-white or
unknown ethnicity, leaving a final sample of 6491
women. Of 8782 children with genotype data, infor-
mation on BMI at around age 9 was available for 5619
(64%), a further 489 (9%) children were excluded due
to non-white or unknown ethnicity, leaving a final
sample of 5130 children.
Copenhagen City Heart Study (CCHS) A prospective
cardiovascular study of individuals selected from the
Central-Population-Register Code designed to reflect the
adult Danish general population, including both men
and women. Those invited were stratified into 5-year
age groups from 20 to 95 years, with main emphasis
placed on the 35- to 70-year olds. In the CCHS, 9252
individuals were available for genotyping and 9238
received a final genotype, 9173 individuals of those
genotyped had data on all measures of adiposity and so
were included in the final analysis. The cohort is very
ethnically homogenous so no participants were
excluded on the basis of ethnicity. The Danish Ethics
Committees for the cities of Copenhagen and Frederiks-
berg approved the study. Informed consent was obtained
from participants.
Measurement of weight at height
Weight and height were measured using standard
procedures and were used to calculate BMI; in all studies
obesity was defined using the WHO standard threshold
of 30 kg/m2 for adults. For the ALSPAC children, the
following cut-offs were used; malesO23.39 kg/m2 and
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females O23.46 kg/m2 (16). In the ALSPAC mothers,
self-reported pre-pregnancy weight and waist and hip
circumference were used, which was obtained at the
18-week antenatal clinic. In the ALSPAC children,
weight and height at around age 9 years measured by
trained nurses at the clinic were used in this analysis. In
the BWHHS, all measurements were undertaken at the
baseline clinical examination and were measured in the
clinic by trained nurses. In the CCHS, the participants
were interviewed at baseline at Rigshospitalet, Copen-
hagen University Hospital and weight and height were
measured.
Genotyping
DNA was extracted by salting out procedure (17).
Genotyping in the ALSPAC and the BWHHS was
undertaken by KBioscience Ltd (www.kbioscience.co.uk),
who use their own form of competitive allele-specific PCR
system (KASPar) and Taqman (Applied Biosystem,
Foster City, CA, USA) for SNP analysis. In the CCHS,
the MTHFR C677T polymorphism was genotyped using
restriction enzymes digesting the PCR product, which
were then separated on a gel (18). Two independent
investigators confirmed each genotype.
Table 2 Distribution of indicators of adiposity by methylenetetrahydrofolate reductase (MTHFR) genotype.
Number (%) for dichotomous variables or mean (S.D.) for continuous variables by
genotype
Outcome variables CC CT TT P
Obese (O30 kg/m2) N (%) N (%) N (%)
BWHHS 360/1525 (23.6) 410/1496 (27.5) 112/395 (28.4) 0.02
CCHS females 315/2454 (12.8) 308/2145 (14.4) 57/465 (12.3) 0.24
CCHS males 273/1946 (14.0) 266/1785 (14.9) 50/378 (13.2) 0.61
CCHS ALL 588/4400 (13.4) 574/3930 (14.6) 107/843 (12.7) 0.16
ALSPAC mothers 163/2870 (5.7) 155/2868 (5.4) 38/753 (5.0) 0.77
ALSPAC girlsa 53/1100 (4.8) 51/1145 (4.4) 18/295 (6.1) 0.50
ALSPAC boysa 62/1170 (5.3) 42/1138 (3.7) 7/282 (2.5) 0.05
ALSPAC children ALL 115/2270 (5.1) 93/2283 (4.1) 25/577 (4.3) 0.27
Body mass index (kg/m2) Mean (S.D.) Mean (S.D.) Mean (S.D.)
BWHHS 27.4 (4.7) NZ1525 27.7 (5.2) NZ1496 27.8 (5.2) NZ395 0.14
CCHS females 25.0 (4.5) NZ2454 25.2 (4.6) NZ2145 24.9 (4.5) NZ465 0.13
CCHS males 26.0 (3.9) NZ1946 26.0 (4.0) NZ1785 25.9 (3.9) NZ378 0.90
CCHS ALL 25.4 (4.3) NZ4400 25.6 (4.4) NZ3930 25 (4.3) NZ843 0.18
ALSPAC mothers 23.0 (3.9) NZ2870 23.0 (3.8) NZ2868 22.9 (3.7) NZ753 0.64
ALSPAC girls 17.8 (2.9) NZ1100 17.8 (2.9) NZ1145 17.9 (3.1) NZ295 0.86
ALSPAC boys 17.6 (2.9) NZ1170 17.3 (2.5) NZ1138 17.3 (2.7) NZ282 0.06
ALSPAC children ALL 17.7 (2.9) NZ2270 17.6 (2.7) NZ2283 17.6 (2.9) NZ577 0.50
Waist–hip ratio
BWHHS 0.82 (0.07) NZ1525 0.82 (0.07) NZ1496 0.82 (0.07) NZ395 0.27
CCHS females 0.83 (0.08) NZ2454 0.83 (0.08) NZ2145 0.83 (0.08) NZ465 0.96
CCHS males 0.94 (0.08) NZ1946 0.95 (0.08) NZ1785 0.95 (0.07) NZ378 0.57
CCHS ALL 0.88 (0.10) NZ4400 0.88 (0.10) NZ3930 0.88 (0.10) NZ843 0.59
ALSPAC mothers 0.74 (0.07) NZ1634 0.74 (0.06) NZ1615 0.74 (0.07) NZ407 0.45
Waist circumference (cm)
BWHHS 85.7 (11.6) NZ1525 86.5 (12.5) NZ1496 86.5 (12.7) NZ395 0.15
CCHS females 99.5 (9.5) NZ2454 99.9 (9.8) NZ2145 99.1 (9.3) NZ465 0.18
CCHS males 100.2 (7.7) NZ1946 100.0 (7.4) NZ1785 99.9 (7.5) NZ378 0.50
CCHS ALL 99.8 (8.7) NZ4400 99.9 (8.8) NZ3930 99.5 (8.5) NZ843 0.36
ALSPAC mothers 68.6 (7.2) NZ1891 68.3 (6.8) NZ1830 68.3 (7.0) NZ491 0.40
aO23.39 kg/m2 males and O23.46 kg/m2 females.
P values are for evidence of heterogeneity across categories (i.e. two degrees of freedom).
Table 1 Distribution of methylenetetrahydrofolate reductase (MTHFR) genotype among the cohorts in this study.
CC CT TT T-allele frequency P for Hardy–Weinberg
BWHHS 1525 (44.7%) 1496 (43.7%) 395 (11.6%) 0.33 0.28
CCHS 4400 (48.0%) 3930 (42.8%) 843 (9.2%) 0.31 0.42
ALSPAC mothers 2870 (44.2%) 2868 (44.1%) 753 (11.6%) 0.34 0.37
ALSPAC boys 1170 (45.2%) 1138 (43.9%) 282 (10.9%) 0.33 0.83
ALSPAC girls 1100 (43.3%) 1145 (45.1%) 295 (11.6%) 0.34 0.91
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Statistical analysis
Assumptions of Hardy–Weinberg equilibrium were
formally tested using a likelihood ratio test. Prevalence
(for dichotomous variables) and means (for continuous
variables) for obesity and other anthropometric measures
were calculated by genotype. One-way ANOVA was used
for testing differences between genotypes for continuous
variables and c2 tests were used for testing differences
between genotypes for dichotomous variables. Pearson c2
tests were used to test for Hardy–Weinberg equilibrium.
Unadjusted odds ratios were calculated for prevalence
of obesity among TT versus CC genotypes, and these
data were used to carry out a formal meta-analysis.
Since the different studies were carried out on diverse
age groups, we carried out three analyses for adults
(CCHS and BWHHS), young women (ALSPAC mothers)
and children (ALSPAC children). Because the results for
the different studies and in different sexes in the ALSPAC
were heterogeneous, we undertook random effects
meta-analyses.
Results
We examined the association between obesity and other
anthropometric measures and MTHFR C677T genotype
in four population-based cohorts totalling 24 210
individuals from the United Kingdom and Denmark. The
mean age of participants in the CCHS was 57.6
(S.D.Z15.2) years (range 21–93) at the time that adiposity
was measured. The mean age of women at early
pregnancy and the time of recruitment into ALSPAC
were 28.5 (S.D.Z4.7) years (range 15–44), the age of
children in the ALSPAC when BMI was measured was 9.9
(S.D.Z0.3) years (range 8.8–11.8). The mean age of
participants in the BWHHS was 68.8 (S.D.Z5.5) years
(range 59–80). The distribution of age did not differ by
genotype in any cohort. T-allele frequencies ranged from
0.31 to 0.34 (Table 1), genotypes were in Hardy–
Weinberg equilibrium in all populations.
We found an association between genotype and
prevalence of obesity (BMI O30 kg/m2) in the
BWHHS, which was not replicated in the other cohorts
(Table 2, and Fig. 1). In the BWHHS, as in the ALSPAC
and CCHS, MTHFR C677T genotype was not associated
with BMI, waist circumference or waist–hip ratio (all
analysed as continuous variables) in adults. In the
ALSPAC boys, there was weak evidence that the CT and
TT genotypes were associated with a reduction in BMI
relative to the CC genotype, and the risk of obesity
appeared to reduce in a dose–response manner with the
number of T-alleles. Our meta-analysis found an overall
odds ratio for obesity in TT versus CC adults of 1.06
(95% CI 0.86–1.32). There was no evidence that
MTHFR C677T was associated with social class,
smoking, alcohol intake or physical activity factors
that may confound an association between folate intake
and obesity (data available from authors).
Figure 1 Forest plot showing risk of obesity amongst MTHFR C677T TT homozygotes versus CC homozygotes.
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Discussion
We found no evidence that the TT genotype of the
MTHFR gene was associated with BMI or obesity in two
out of three of our adult cohorts, which suggests that
the initial positive finding with obesity in the BWHHS
was a chance finding arising due to the large number of
association tests that were performed between this
genotype and phenotypes in the BWHHS. This empha-
sizes the need to replicate positive associations in other
studies in order to guard against the problem of multiple
testing. We found that among boys in the ALSPAC
cohort, who were around age 9 at the time of
measurement, the T-allele was associated with a
reduction in the prevalence of obesity and a reduction
in BMI. This most likely could also be a chance finding,
but requires further investigation to clarify whether this
is the case or whether there is in fact evidence of a
protective effect of the T-allele in pre-adolescent boys.
We have used a genetic variant that influences
circulating folate levels to test whether low folate
availability is a risk factor for obesity. This analysis is
not subject to reverse causation since an individual’s
genotype is determined at conception and cannot be
determined by an individual’s weight later in life. In
addition, this genetic variant that affects the metabolism
of folate, for instance, does not appear to be associated
with other dietary and lifestyle factors, which are
typically associated with dietary folate intake (8–10).
Our findings are consistent with a small study on
obesity carried out in Spain (19) and also an Italian
study, which found no association between this
genotype and metabolic syndrome (20). These findings
argue against a role for methylation in determining
adult and childhood obesity, particularly as the MTHFR
C677T TT homozygotes have been shown to exhibit a
diminished level of DNA methylation compared with CC
homozygotes (21). However, we are unable to shed any
light on whether those who have a greater BMI also
have a greater requirement for folate, this question
requires further research. A recent family study has
suggested that polymorphisms in this gene may be
related to lean body mass rather than fat mass (22),
whilst our study of BMI (which is a composite of the
two) does not support these findings; in this analysis, we
did not look at lean body mass separately as lean mass
was not measured in all our populations, this hypothesis
therefore requires further investigation.
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